Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved..
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 3(2022), 7 vom: 19. Juli, Seite 100685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Weskamm, Leonie M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.07.2022 Date Revised 08.09.2022 published: Print ClinicalTrials.gov: NCT03615911 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2022.100685 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343786427 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343786427 | ||
| 003 | DE-627 | ||
| 005 | 20231226021246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2022.100685 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343786427 | ||
| 035 | |a (NLM)35858586 | ||
| 035 | |a (PII)S2666-3791(22)00221-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Weskamm, Leonie M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2022 | ||
| 500 | |a Date Revised 08.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03615911 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a IgG ELISpot | |
| 650 | 4 | |a IgG subclasses | |
| 650 | 4 | |a MERS-CoV | |
| 650 | 4 | |a MVA-MERS-S | |
| 650 | 4 | |a immune persistence | |
| 650 | 4 | |a late booster vaccination | |
| 650 | 4 | |a long-term immunity | |
| 650 | 4 | |a memory B cells | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a viral vector vaccine | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Fathi, Anahita |e verfasserin |4 aut | |
| 700 | 1 | |a Raadsen, Matthijs P |e verfasserin |4 aut | |
| 700 | 1 | |a Mykytyn, Anna Z |e verfasserin |4 aut | |
| 700 | 1 | |a Koch, Till |e verfasserin |4 aut | |
| 700 | 1 | |a Spohn, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Friedrich, Monika |e verfasserin |4 aut | |
| 700 | 0 | |a MVA-MERS-S Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Sutter, Gerd |e verfasserin |4 aut | |
| 700 | 1 | |a Dahlke, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Addo, Marylyn M |e verfasserin |4 aut | |
| 700 | 1 | |a Bartels, Etienne |e investigator |4 oth | |
| 700 | 1 | |a Gundlach, Swantje |e investigator |4 oth | |
| 700 | 1 | |a Hesterkamp, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Krähling, Verena |e investigator |4 oth | |
| 700 | 1 | |a Lassen, Susan |e investigator |4 oth | |
| 700 | 1 | |a Ly, My Linh |e investigator |4 oth | |
| 700 | 1 | |a Pötsch, Joseph H |e investigator |4 oth | |
| 700 | 1 | |a Schmiedel, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Volz, Asisa |e investigator |4 oth | |
| 700 | 1 | |a Zinser, Madeleine E |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 3(2022), 7 vom: 19. Juli, Seite 100685 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:7 |g day:19 |g month:07 |g pages:100685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2022.100685 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 7 |b 19 |c 07 |h 100685 | ||